Table 1.
Characteristics of evaluable patients (n=35).
| Characteristic | Number of cases | % |
|---|---|---|
| Age | ||
| <40 | 6 | 17.1 |
| 40–49 | 15 | 42.9 |
| 50–59 | 10 | 28.6 |
| 60–69 | 3 | 8.6 |
| >70 | 1 | 2.9 |
| Race | ||
| African American | 3 | 8.6 |
| Hispanic | 0 | 0.0 |
| American Indian | 1 | 2.9 |
| White | 30 | 85.7 |
| Unreported | 1 | 2.9 |
| Performance status | ||
| 0 | 19 | 54.3 |
| 1 | 10 | 28.6 |
| 2 | 6 | 17.1 |
| Cell type | ||
| Squamous | 22 | 62.8 |
| Adenocarcinoma | 9 | 25.7 |
| Small cell | 1 | 2.9 |
| Endometrioid adenocarcinoma | 1 | 2.9 |
| Undifferentiated | 1 | 2.9 |
| Adenosquamous | 1 | 2.9 |
| Grade | ||
| 1 | 3 | 8.6 |
| 2 | 17 | 48.6 |
| 3 | 14 | 40.0 |
| Unspecified | 1 | 2.9 |
| Prior chemotherapy | ||
| 1 regimen | 35 | 100.0 |
| Prior radiation | 27 | 77.1 |
| Cycles of treatment | ||
| 1 | 2 | 5.7 |
| 2 | 10 | 28.6 |
| 3 | 2 | 5.7 |
| 4 | 5 | 14.3 |
| 5 | 2 | 5.7 |
| >5 | 14 | 40.0 |